ENVI strengthens case for non-viables as it tackles ethically-controversial issues
This article was originally published in Clinica
Executive Summary
The latest draft report put together by Miroslav Mikolasik, rapporteur at the European Parliament's Committee on the Environment Public Health and Food Safety (ENVI), on the European Commission's proposed Advanced Therapies Medicinal Products (ATMP) Regulation, is currently devoid of any of the ethically-controversial issues that caused it to founder when MEPs last voted on the text.